Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Design Of Experiment Approach In Development Of Febuxostat Nanocrystal: Application Of Soluplus® As Stabilizer

O. P. Sharma, Viral Patel, T. Mehta
Published 2016 · Materials Science

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Abstract The objective of present study was to explore the application of Soluplus® as a stabilizer for the preparation of febuxostat (FEB) nanocrystals using ball milling technique. Preliminary trials were performed for the selection of stabilizer from HPMC VLV, PVA, PVP K30, Poloxamer 188 and Soluplus®. Soluplus® stabilized FEB nanocrystals were found stable and had least particle size as compared to the batches prepared using other stabilizers. A systematic optimization of critical process parameters, stirring time and amount of bead, of ball milling process was performed with aid of central composite design. Particle size (D50 and D90) and the size distribution (SPAN) were taken as responses for the evaluation of design batches and were used as the criteria for selection of optimized batch. Optimized formulation was characterized using SEM, XRD and DSC, depicted conversion of crystalline FEB into amorphous form having 26.08 times (in pH 1.2) and 1.67 times (in pH 6.0) more saturation solubility. In vitro drug dissolution study showed 9 times faster drug release while in vivo pharmacokinetic study showed an increase in oral bioavailability, Cmax and AUC, of FEB nanocrystals as compared to FEB API. Thus, current study supports the suitability of Soluplus® as stabilizer for the preparation of FEB nanocrystals.
This paper references
10.1016/J.IJPHARM.2004.08.001
The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.
Y. Wu (2004)
10.3109/03639045.2011.645830
Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation
T. Jiang (2012)
10.1016/j.ijpharm.2014.10.025
Investigation of a nanosuspension stabilized by Soluplus® to improve bioavailability.
Hua Yang (2014)
10.1016/j.clinthera.2009.11.033
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
M. Ernst (2009)
10.1023/A:1016051316815
Formulation and Antitumor Activity Evaluation of Nanocrystalline Suspensions of Poorly Soluble Anticancer Drugs
E. Merisko-Liversidge (2004)
10.1016/j.ijpharm.2013.10.001
Effects of particle size on the pharmacokinetics of puerarin nanocrystals and microcrystals after oral administration to rat.
Liangxing Tu (2013)
10.3109/03639045.2014.954585
Design and evaluation of injectable niclosamide nanocrystals prepared by wet media milling technique
Yanghuan Ye (2015)
10.1016/J.POWTEC.2015.05.012
Amorphous formulations for dissolution and bioavailability enhancement of poorly soluble APIs
P. Kanaujia (2015)
10.1111/j.2042-7158.2010.01022.x
Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods
L. Peltonen (2010)
10.1016/j.ejps.2012.08.011
Optimization of formulation and process parameters for the production of nanosuspension by wet media milling technique: effect of Vitamin E TPGS and nanocrystal particle size on oral absorption.
Indrajit K. Ghosh (2012)
10.1016/j.ejps.2013.09.002
Impact of process parameters on the breakage kinetics of poorly water-soluble drugs during wet stirred media milling: a microhydrodynamic view.
A. Afolabi (2014)
10.1021/CG400583Z
Soluble Cocrystals of the Xanthine Oxidase Inhibitor Febuxostat
D. Maddileti (2013)
10.1016/j.jconrel.2013.08.006
Stability of nanosuspensions in drug delivery.
Y. Wang (2013)
Formulation and Evaluation of Poorly Soluble Febuxostat Orodispersable Tablet
K. K. Kumar (2014)
10.2147/IJN.S595
Nanocrystal technology, drug delivery and clinical applications
Jens-Uwe A. H. Junghanns (2008)
10.1517/17425247.2014.944861
Formulation optimization of gastroretentive drug delivery system for allopurinol using experimental design
O. P. Sharma (2015)
10.1016/J.CEJ.2011.12.044
Liquid antisolvent precipitation and stabilization of nanoparticles of poorly water soluble drugs in aqueous suspensions: Recent developments and future perspective
Alpana Ankush Thorat (2012)
10.1016/j.ejps.2011.11.025
Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo.
M. Linn (2012)
10.1016/j.ijpharm.2014.12.003
Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
Bhupesh K Ahuja (2015)
10.1016/J.JCONREL.2005.11.013
Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs.
Jun-ichi Jinno (2006)
10.1016/J.AJPS.2014.08.005
Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs
V. Junyaprasert (2015)
10.1081/DDC-120030422
Nanoparticle Engineering Processes for Enhancing the Dissolution Rates of Poorly Water Soluble Drugs
Jiahui Hu (2004)
10.1080/03639040701741810
Preparation and Characterization of an Oridonin Nanosuspension for Solubility and Dissolution Velocity Enhancement
L. Gao (2007)
10.1021/la9016432
Scanning probe microscopy method for nanosuspension stabilizer selection.
S. Verma (2009)
10.3109/03639045.2015.1082581
Design of experiment approach for formulating multi-unit colon-targeted drug delivery system: in vitro and in vivo studies
N. Shah (2016)
10.1016/J.POWTEC.2012.12.038
Soluplus®: A novel polymeric solubilizer for optimization of Carvedilol solid dispersions: Formulation design and effect of method of preparation
R. Shamma (2013)
10.1016/j.ijpharm.2015.03.009
Solid formulations by a nanocrystal approach: critical process parameters regarding scale-ability of nanocrystals for tableting applications.
A. Tuomela (2015)
10.1111/J.1365-2125.2007.03016.X
Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.
R. Khosravan (2008)
10.3109/03639045.2012.746362
Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation
G. V. Patel (2014)
10.3109/03639045.2014.971027
Solubility and dissolution enhancement strategies: current understanding and recent trends*
S. Jain (2015)
10.1016/j.colsurfb.2015.08.042
Preparation and pharmacodynamic assessment of ezetimibe nanocrystals: Effect of P-gp inhibitory stabilizer on particle size and oral absorption.
K. Srivalli (2015)
10.1016/J.POWTEC.2014.03.001
Design and development of solid nanoparticulate dosage forms of telmisartan for bioavailability enhancement by integration of experimental design and principal component analysis
J. Patel (2014)



This paper is referenced by
Application and Functional Characterization of Kollicoat Smartseal 30D as a Solid Dispersion Carrier for Improving Solubility
Chivate Amit (2020)
10.1016/J.POWTEC.2017.02.038
Enhanced oral bioavailability and diminished food effect of lurasidone hydrochloride nanosuspensions prepared by facile nanoprecipitation based on dilution
P. Yu (2017)
10.35333/jrp.2019.65
Optimization and evaluation of cyclosporine A nanosuspension stabilized by combination stabilizers using high pressure homogenization method
Sıla Gülbağ Pinar (2019)
10.1186/s40824-020-0184-8
Emerging role of nanosuspensions in drug delivery systems
Shery Jacob (2020)
10.3390/CRYST8020085
Febuxostat-Minoxidil Salt Solvates: Crystal Structures, Characterization, Interconversion and Solubility Performance
Li-Yang Li (2018)
10.1016/J.JDDST.2018.06.005
Enhancement of in vitro dissolution and in vivo performance/oral absorption of FEB-poloxamer-TPGS solid dispersion
X. Sheng (2018)
10.1080/10837450.2017.1315135
Significant solubility of carbon dioxide in Soluplus® facilitates impregnation of ibuprofen using supercritical fluid technology
R. Obaidat (2018)
10.1080/03639045.2018.1503296
A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes
Pooja J Patel (2018)
10.1080/17425247.2018.1444025
Nanocrystal: a novel approach to overcome skin barriers for improved topical drug delivery
V. Patel (2018)
10.1016/j.ijpharm.2020.119727
Hybridized Nanoamorphous Micellar Dispersion Using a QbD-DM3 Linked Rational Product Design Strategy for Ritonavir: a BCS IV Drug.
V. Rathod (2020)
10.1111/jphp.12857
Studies on the curcumin phospholipid complex solidified with Soluplus®
Jianan Wang (2018)
10.1208/s12249-019-1578-6
Enhanced Physical Stability and Synchronized Release of Febuxostat and Indomethacin in Coamorphous Solids
Sakib M. Moinuddin (2020)
10.1080/02652048.2018.1526339
Preparation, optimisation, and in vitro–in vivo evaluation of febuxostat ternary solid dispersion
Jingjing Tang (2018)
10.1208/s12249-019-1368-1
Impact of Process Parameters on Particle Size Involved in Media Milling Technique Used for Preparing Clotrimazole Nanocrystals for the Management of Cutaneous Candidiasis
V. Patel (2019)
10.1208/s12249-020-01777-y
Nanocrystals of Novel Valerolactam-Fenbendazole Hybrid with Improved in vitro Dissolution Performance
Maria Elisa Melian (2020)
10.1208/s12249-020-01876-w
Mechanistic Modeling of Wet Stirred Media Milling for Production of Drug Nanosuspensions.
E. Bilgili (2020)
Semantic Scholar Logo Some data provided by SemanticScholar